Hcor utilises Oracle Clinical One for independent phase 3 immunology studies

Brazil's Hcor harnesses Oracle's cloud solutions to independently manage critical immunology trials, reducing costs and accelerating execution.

Brazil-based research organisation, Hcor, has taken a significant step by employing Oracle Clinical One Data Collection to advance its critical phase 3 immunology studies. Previously reliant on third-party firms, Hcor often faced added time and complexity in study builds. The transition to Oracle's modern, cloud-based data collection platform now allows Hcor to manage these studies autonomously resulting in reduced costs and accelerated trial execution.

Oracle Clinical One Data Collection, anchored on the security, performance, and scalability of Oracle Cloud Infrastructure, is part of the company's extensive life sciences solutions portfolio.

Hcor is not just a hospital specialising in cardiology, oncology, and other healthcare fields; it's also a renowned research institute recognised for its innovation and role in clinical trials. This partnership with Oracle is no exception. “With Oracle Clinical One Data Collection, we have built two important immunology trials independently using Oracle’s robust and reliable platform, which can help to accelerate potentially life-changing clinical trials,” said Research Institute Manager, Tamiris Abait Miranda.

Oracle's approach to electronic data capture offers life sciences organisations new ways to gather datasets from diverse sources. The system helps unlock valuable insights, freeing Hcor from third-party dependencies.

Recognised as an electronic data capture leader by the Everest Group PEAK Matrix, Oracle's platform excels with its intuitive, user-friendly design. It simplifies study builds and facilitates real-time adjustments, eliminating the need for costly programming or intervention. This capability not only expedites trial timelines but also helps cut down on build times.

"Our unified platform helps organisations like Hcor make it easier to build studies independently and have more flexibility and control throughout the entire trial lifecycle," said Seema Verma, Oracle executive vice president. She emphasised Oracle's mission of leveraging the latest AI and cloud technology to revolutionise study conduct, ensuring patient-centric solutions and accelerated regulatory submissions.

Additionally, Hcor benefits from Oracle Exadata Cloud@Customer’s low latency and high computing power. By transitioning its workloads, Hcor has boosted IT performance by 20%, with developers launching projects five times faster. The overhaul has significantly enhanced system security, project completion rates, and patient care efficiencies.

The collaboration between Hcor and Oracle showcases a transformative approach in clinical research, emphasising the importance of technology in driving healthcare innovation and patient-centric care.

Emerge research finds that AI investments are now under stricter timelines, compelling leaders to...
Red Hat collaborates with the UK MOD to provide centralised cloud-native platforms aimed at...
Node4 has become an Engage Tech Support Partner within Fortinet's program, strengthening its...
Exclusive Networks partners with Extreme Networks to enhance AI-driven cloud solutions across the...
SentinelOne expands its AI Security Platform with new DSPM features to help secure AI systems amid...
Cisco's latest advancements aim to provide a foundation for AI, emphasising security and...
Birmingham City University partners with Exponential-e to implement a cloud-based communications...
Portnox expands its Zero Trust Network Access solution by including console-based applications,...